Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01

Reuters

Nov 08

Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01

Evaxion A/S has announced new biomarker and immune data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine. The data were presented at the Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting. The phase 2 trial evaluates EVX-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. According to Evaxion, the new results include analyses of immune responses, with longitudinal blood samples collected to characterize changes in T-cell populations. In certain patient subsets, clinical responses were associated with rapid and sustained induction of EVX-01-specific T-cells. These findings build on two-year clinical efficacy data previously presented at the European Society for Medical Oncology 2025 congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137616-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581834041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581834041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581834041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 06:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581834041","market":"nz","top_or_hot":-1,"title":"Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evaxion A/S has announced new biomarker and immune data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine. The data were presented at the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 2025 Annual Meeting. The phase 2 trial evaluates EVX-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. According to Evaxion, the new results include analyses of immune responses, with longitudinal blood samples collected to characterize changes in T-cell populations. In certain patient subsets, clinical responses were associated with rapid and sustained induction of EVX-01-specific T-cells. These findings build on two-year clinical efficacy data previously presented at the European Society for Medical Oncology 2025 congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137616-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-08 06:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evaxion A/S has announced new biomarker and immune data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine. The data were presented at the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 2025 Annual Meeting. The phase 2 trial evaluates EVX-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. According to Evaxion, the new results include analyses of immune responses, with longitudinal blood samples collected to characterize changes in T-cell populations. In certain patient subsets, clinical responses were associated with rapid and sustained induction of EVX-01-specific T-cells. These findings build on two-year clinical efficacy data previously presented at the European Society for Medical Oncology 2025 congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137616-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVAX","symbol_name":"Evaxion Biotech A/S","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDLbJWzvZ:1","article_id":"2581834041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581834041","pubTimestamp":1762553414,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evaxion A/S has announced new biomarker and immune data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine. The data were presented at the Society for Immunotherapy of Cancer  2025 Annual Meeting. The phase 2 trial evaluates EVX-01 in combination with KEYTRUDA  in patients with advanced melanoma. According to Evaxion, the new results include analyses of immune responses, with longitudinal blood samples collected to characterize changes in T-cell populations. In certain patient subsets, clinical responses were associated with rapid and sustained induction of EVX-01-specific T-cells. These findings build on two-year clinical efficacy data previously presented at the European Society for Medical Oncology 2025 congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVAX":"Evaxion Biotech A/S","BK4139":"生物科技"},"translate_title":"Evaxion公布AI设计癌症疫苗EVX-01 2期试验新免疫数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVAX":0.9},"content_text":"Evaxion Unveils New Immune Data From Phase 2 Trial of AI-Designed Cancer Vaccine EVX-01\n    \n\n        Evaxion A/S has announced new biomarker and immune data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine. The data were presented at the Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting. The phase 2 trial evaluates EVX-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. According to Evaxion, the new results include analyses of immune responses, with longitudinal blood samples collected to characterize changes in T-cell populations. In certain patient subsets, clinical responses were associated with rapid and sustained induction of EVX-01-specific T-cells. These findings build on two-year clinical efficacy data previously presented at the European Society for Medical Oncology 2025 congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137616-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}